Qilu Pharmaceutical Announces Positive Phase Ia Study Results of QLS32015 at ASH 2024 The preliminary results of Qilu Pharmaceutical's Phase Ia study on QLS32015 for multiple myeloma showed promising anti-tumor activity and tolerability.

Qilu Pharmaceutical Announces Positive Phase Ia Study Results of QLS32015 at ASH 2024 #China #Jinan #ASH_2024 #Qilu_Pharmaceutical #QLS32015